Why Most Biomedical Findings Echoed by Newspapers Turn Out to be False: The Case of Attention Deficit Hyperactivity Disorder

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Gonon, François ^a,b   Konsman, Jan Pieter ^a,c   Cohen, David ^d   Boraud, Thomas ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c CNRS University Bordeaux Segalen   (France)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; GLUCOSE; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; BIBLIOGRAPHIC DATABASE; CONTENT ANALYSIS; DATA ANALYSIS; FACTIVA DATABASE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE METABOLISM; HEALTH SCIENCE; HUMAN; JOURNAL IMPACT FACTOR; MASS MEDIUM; MEDICAL INFORMATION; MEDLINE; POSITRON EMISSION TOMOGRAPHY; PUBLICATION; SCIENTIFIC LITERATURE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOMEDICAL RESEARCH; COMMUNICATIONS MEDIA; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JOURNAL IMPACT FACTOR; META-ANALYSIS AS TOPIC; NEWSPAPERS; RECEPTORS, DOPAMINE D4; SUBSTANCE-RELATED DISORDERS; UNIVERSITIES;

EID: 84866341581     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044275     Document Type: Article

References (99)

1. Bubela TM, Caulfield TA, (2004) Do the print media "hype" genetic research? A comparison of newspaper stories and peer-reviewed research papers. CMAJ 170: 1399-1407.
2. Schwitzer G, (2008) How do US journalists cover treatments, tests, products, and procedures? An evaluation of 500 stories. PLoS Med 5: e95.
3. Iaboli L, Caselli L, Filice A, Russi G, Belletti E, (2010) The unbearable lightness of health science reporting: a week examining Italian print media. PLoS ONE 5: e9829.
4. Bubela T, Nisbet MC, Borchelt R, Brunger F, Critchley C, et al. (2009) Science communication reconsidered. Nat Biotechnol 27: 514-518.
5. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JP, (2008) Life cycle of translational research for medical interventions. Science 321: 1298-1299.
6. Ioannidis JP, (2005) Contradicted and initially stronger effects in highly cited clinical research. JAMA 294: 218-228.
7. Ioannidis JP, (2005) Why most published research findings are false. PLoS Med 2: e124.
8. Ioannidis JP, Panagiotou OA, (2011) Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 305: 2200-2210.
9. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR, (1991) Publication bias in clinical research. Lancet 337: 867-872.
10. Faraone SV, Sergeant J, Gillberg C, Biederman J, (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2: 104-113.
11. Taylor E (2006) Hyperkinetic disorders. In: Gillberg C, Harrington R, Steinhausen HC, editors. A clinician handbook of child and adolescent psychiatry. Cambridge: Cambridge University Press. pp. 489-521.
12. Pelham WE, Fabiano GA, (2008) Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol 37: 184-214.
13. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, et al. (2008) Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: A naturalistic controlled 10-year follow-up study. Am J Psychiatry 165: 597-603.
14. Molina BS, Flory K, Hinshaw SP, Greiner AR, Arnold LE, et al. (2007) Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46: 1028-1040.
15. Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, et al. (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48: 484-500.
16. Mayes R, Bagwell C, Erkulwater J, (2008) ADHD and the rise in stimulant use among children. Harv Rev Psychiatry 16: 151-166.
17. Zametkin AJ, Nordahl TE, Gross M, King AC, Semple WE, et al. (1990) Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 323: 1361-1366.
18. LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, et al. (1996) Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1: 121-124.
19. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, et al. (1998) Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A 95: 14494-14499.
20. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, et al. (1999) Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354: 2132-2133.
21. Hauser P, Zametkin AJ, Martinez P, Vitiello B, Matochik JA, et al. (1993) Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone. N Engl J Med 328: 997-1001.
22. Wolraich ML, Lindgren SD, Stumbo PJ, Stegink LD, Appelbaum MI, et al. (1994) Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. N Engl J Med 330: 301-307.
23. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV, (1999) Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104: e20.
24. The MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56: 1073-1086.
25. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, et al. (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283: 397-401.
26. Safer DJ, Zito JM, Fine EM, (1996) Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 98: 1084-1088.
27. Zametkin AJ, Liebenauer LL, Fitzgerald GA, King AC, Minkunas DV, et al. (1993) Brain metabolism in teenagers with attention-deficit hyperactivity disorder. Arch Gen Psychiatry 50: 333-340.
28. Ernst M, Liebenauer LL, King AC, Fitzgerald GA, Cohen RM, et al. (1994) Reduced brain metabolism in hyperactive girls. J Am Acad Child Adolesc Psychiatry 33: 858-868.
29. Ernst M, Cohen RM, Liebenauer LL, Jons PH, Zametkin AJ, (1997) Cerebral glucose metabolism in adolescent girls with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36: 1399-1406.
30. Ernst M, Zametkin AJ, Phillips RL, Cohen RM, (1998) Age-related changes in brain glucose metabolism in adults with attention-deficit/hyperactivity disorder and control subjects. J Neuropsychiatry Clin Neurosci 10: 168-177.
31. Rowe DC, Stever C, Giedinghagen LN, Gard JM, Cleveland HH, et al. (1998) Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol Psychiatry 3: 419-426.
32. Comings DE, Gonzalez N, Wu S, Gade R, Muhleman D, et al. (1999) Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet 88: 358-368.
33. Hawi Z, McCarron M, Kirley A, Daly G, Fitzgerald M, et al. (2000) No association of the dopamine DRD4 receptor (DRD4) gene polymorphism with attention deficit hyperactivity disorder (ADHD) in the Irish population. Am J Med Genet 96: 268-272.
34. Holmes J, Payton A, Barrett JH, Hever T, Fitzpatrick H, et al. (2000) A family-based and case-control association study of the dopamine D4 receptor gene and dopamine transporter gene in attention deficit hyperactivity disorder. Mol Psychiatry 5: 523-530.
35. Muglia P, Jain U, Macciardi F, Kennedy JL, (2000) Adult attention deficit hyperactivity disorder and the dopamine D4 receptor gene. Am J Med Genet 96: 273-277.
36. Curran S, Mill J, Sham P, Rijsdijk F, Marusic K, et al. (2001) QTL association analysis of the DRD4 exon 3 VNTR polymorphism in a population sample of children screened with a parent rating scale for ADHD symptoms. Am J Med Genet 105: 387-393.
37. Mill J, Curran S, Kent L, Richards S, Gould A, et al. (2001) Attention deficit hyperactivity disorder (ADHD) and the dopamine D4 receptor gene: evidence of association but no linkage in a UK sample. Mol Psychiatry 6: 440-444.
38. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, et al. (2001) Attention-deficit hyperactivity disorder: a study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am J Med Genet 105: 471-478.
39. Smith KM, Daly M, Fischer M, Yiannoutsos CT, Bauer L, et al. (2003) Association of the dopamine beta hydroxylase gene with attention deficit hyperactivity disorder: genetic analysis of the Milwaukee longitudinal study. Am J Med Genet B Neuropsychiatr Genet 119B: 77-85.
40. El-Faddagh M, Laucht M, Maras A, Vohringer L, Schmidt MH, (2004) Association of dopamine D4 receptor (DRD4) gene with attention-deficit/hyperactivity disorder (ADHD) in a high-risk community sample: a longitudinal study from birth to 11 years of age. J Neural Transm 111: 883-889.
41. Frank Y, Pergolizzi RG, Perilla MJ, (2004) Dopamine D4 receptor gene and attention deficit hyperactivity disorder. Pediatr Neurol 31: 345-348.
42. Carrasco X, Rothhammer P, Moraga M, Henriquez H, Chakraborty R, et al. (2006) Genotypic interaction between DRD4 and DAT1 loci is a high risk factor for attention-deficit/hyperactivity disorder in Chilean families. Am J Med Genet B Neuropsychiatr Genet 141B: 51-54.
43. Gornick MC, Addington A, Shaw P, Bobb AJ, Sharp W, et al. (2007) Association of the dopamine receptor D4 (DRD4) gene 7-repeat allele with children with attention-deficit/hyperactivity disorder (ADHD): an update. Am J Med Genet B Neuropsychiatr Genet 144B: 379-382.
44. Johansson S, Halleland H, Halmoy A, Jacobsen KK, Landaas ET, et al. (2008) Genetic analyses of dopamine related genes in adult ADHD patients suggest an association with the DRD5-microsatellite repeat, but not with DRD4 or SLC6A3 VNTRs. Am J Med Genet B Neuropsychiatr Genet 147B: 1470-1475.
45. Martinez-Levy G, John DG, Magdalena BV, Ariadna GS, Francisco de LP, et al. (2009) Genetic interaction analysis for DRD4 and DAT1 genes in a group of Mexican ADHD patients. Neurosci Lett 451: 257-260.
46. Gizer IR, Ficks C, Waldman ID, (2009) Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 126: 51-90.
47. Smith TF, (2010) Meta-analysis of the heterogeneity in association of DRD4 7-repeat allele and AD/HD: stronger association with AD/HD combined type. Am J Med Genet B Neuropsychiatr Genet 153B: 1189-1199.
48. Dresel S, Krause J, Krause KH, LaFougere C, Brinkbaumer K, et al. (2000) Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 27: 1518-1524.
49. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, et al. (2003) Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 30: 306-311.
50. Larisch R, Sitte W, Antke C, Nikolaus S, Franz M, et al. (2006) Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl Med Commun 27: 267-270.
51. la Fougere C, Krause J, Krause KH, Josef Gildehaus F, Hacker M, et al. (2006) Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl Med Commun 27: 733-737.
52. van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, et al. (2002) Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 159: 309-312.
53. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L, (2005) Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 57: 229-238.
54. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, et al. (2007) Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 34: 1182-1190.
55. Hesse S, Ballaschke O, Barthel H, Sabri O, (2009) Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res 171: 120-128.
56. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, et al. (2009) Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 302: 1084-1091.
57. Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, et al. (2007) Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry 62: 1059-1061.
58. Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, et al. (2005) In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry 57: 1293-1300.
59. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U, (2012) Striatal Dopamine Transporter Alterations in ADHD: Pathophysiology or Adaptation to Psychostimulants? A Meta-Analysis. Am J Psychiatry.
60. Findling RL, (1996) Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. Journal of American Academy of Child & Adolescent Psychiatry 6: 165-175.
61. Popper CW, (1997) Antidepressants in the treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry 58: 14-29 discussion 30-11.
62. Weiss M, Hechtman L, (2006) A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 67: 611-619.
63. Faraone SV, (2009) Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. Pharmacol Therapeut 34: 678-694.
64. Faraone SV, Glatt SJ, (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71: 754-763.
65. Weiss RE, Stein MA, Trommer B, Refetoff S, (1993) Attention-deficit hyperactivity disorder and thyroid function. J Pediatr 123: 539-545.
66. Spencer T, Biederman J, Wilens T, Guite J, Harding M, (1995) ADHD and thyroid abnormalities: a research note. J Child Psychol Psychiatry 36: 879-885.
67. Valentine J, Rossi E, O'Leary P, Parry TS, Kurinczuk JJ, et al. (1997) Thyroid function in a population of children with attention deficit hyperactivity disorder. J Paediatr Child Health 33: 117-120.
68. Weiss RE, Stein MA, Duck SC, Chyna B, Phillips W, et al. (1994) Low intelligence but not attention deficit hyperactivity disorder is associated with resistance to thyroid hormone caused by mutation R316H in the thyroid hormone receptor beta gene. J Clin Endocrinol Metab 78: 1525-1528.
69. Hauser P, Soler R, Brucker-Davis F, Weintraub BD, (1997) Thyroid hormones correlate with symptoms of hyperactivity but not inattention in attention deficit hyperactivity disorder. Psychoneuroendocrinology 22: 107-114.
70. Weiss RE, Stein MA, Refetoff S, (1997) Behavioral effects of liothyronine (L-T3) in children with attention deficit hyperactivity disorder in the presence and absence of resistance to thyroid hormone. Thyroid 7: 389-393.
71. Wolraich ML, Wilson DB, White JW, (1995) The effect of sugar on behavior or cognition in children. A meta-analysis. JAMA 274: 1617-1621.
72. Bachorowski JA, Newman JP, Nichols SL, Gans DA, Harper AE, et al. (1990) Sucrose and delinquency: behavioral assessment. Pediatrics 86: 244-253.
73. Saravis S, Schachar R, Zlotkin S, Leiter LA, Anderson GH, (1990) Aspartame: effects on learning, behavior, and mood. Pediatrics 86: 75-83.
74. Wender EH, Solanto MV, (1991) Effects of sugar on aggressive and inattentive behavior in children with attention deficit disorder with hyperactivity and normal children. Pediatrics 88: 960-966.
75. Swanson JM, Lerner M, Williams L, (1995) More frequent diagnosis of attention deficit-hyperactivity disorder. N Engl J Med 333: 944.
76. LeFever GB, Dawson KV, Morrow AL, (1999) The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health 89: 1359-1364.
77. Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, et al. (1999) Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 153: 1257-1263.
78. Robinson LM, Sclar DA, Skaer TL, Galin RS, (1999) National Trends in the Prevalence of Attention-Deficit/Hyperactivity Disorder and the Prescribing of Methylphenidate among School-Age Children: 1990-1995. Clin Pediatr 38: 209-217.
79. Olfson M, Marcus SC, Weissman MM, Jensen PS, (2002) National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41: 514-521.
80. Olfson M, Gameroff MJ, Marcus SC, Jensen PS, (2003) National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 160: 1071-1077.
81. Wilens TE, Faraone SV, Biederman J, Gunawardene S, (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111: 179-185.
82. Lambert NM, Hartsough CS, (1998) Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 31: 533-544.
83. Barkley RA, Fischer M, Smallish L, Fletcher K, (2003) Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 111: 97-109.
84. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, et al. (2005) Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 15: 764-776.
85. Wilens TE, Adamson J, Monuteaux MC, Faraone SV, Schillinger M, et al. (2008) Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med 162: 916-921.
86. Faraone SV, Biederman J, Wilens TE, Adamson J, (2007) A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med 37: 1743-1752.
87. Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM, (2008) Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 28: 783-800.
88. Dopfner M, Breuer D, Schurmann S, Metternich TW, Rademacher C, et al. (2004) Effectiveness of an adaptive multimodal treatment in children with Attention-Deficit Hyperactivity Disorder - global outcome. Eur Child Adolesc Psychiatry 13 Suppl 1: I117-129.
89. The MTA Cooperative Group (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113: 762-769.
90. Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, et al. (2007) 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 46: 989-1002.
91. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, et al. (2008) Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord 12: 4-14.
92. Woloshin S, Schwartz LM, Casella SL, Kennedy AT, Larson RJ, (2009) Press releases by academic medical centers: not so academic? Ann Intern Med 150: 613-618.
93. Holtzman NA, Bernhardt BA, Mountcastle-Shah E, Rodgers JE, Tambor E, et al. (2005) The quality of media reports on discoveries related to human genetic diseases. Community Genet 8: 133-144.
94. Mill J, Petronis A, (2008) Pre- and peri-natal environmental risks for attention-deficit hyperactivity disorder (ADHD): the potential role of epigenetic processes in mediating susceptibility. J Child Psychol Psychiatry 49: 1020-1030.
95. Ficks CA, Waldman ID, (2009) Gene-environment interactions in attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 11: 387-392.
96. Sonuga-Barke EJ, (2010) Editorial: 'It's the environment stupid!' On epigenetics, programming and plasticity in child mental health. J Child Psychol Psychiatry 51: 113-115.
97. Phillips DP, Kanter EJ, Bednarczyk B, Tastad PL, (1991) Importance of the lay press in the transmission of medical knowledge to the scientific community. N Engl J Med 325: 1180-1183.
98. Gonon F, Bezard E, Boraud T, (2011) What should be said to the lay public regarding ADHD etiology. Am J Med Genet B Neuropsychiatr Genet 156: 989-991.
99. Schwartz LM, Woloshin S, Andrews A, Stukel TA, (2012) Influence of medical journal press releases on the quality of associated newspaper coverage: retrospective cohort study. BMJ 344: d8164.